Please use this identifier to cite or link to this item:
Title: A multicentre randomised controlled trial of levetiracetam versus phenytoin for convulsive status epilepticus in children (protocol): Convulsive Status Epilepticus Paediatric Trial (ConSEPT) - a PREDICT study
Authors: Dalziel, Stuart R
Furyk, Jeremy
Bonisch, Megan
Oakley, Ed
Borland, Meredith
Neutze, Jocelyn
Donath, Susan
Sharpe, Cynthia
Harvey, Simon
Davidson, Andrew
Craig, Simon
Phillips, Natalie 
George, Shane 
Rao, Arjun
Cheng, Nicholas
Zhang, Michael
Sinn, Kam
Kochar, Amit
Brabyn, Christine
Babl, Franz E
Issue Date: 22-Jun-2017
Publisher: BMC
Source: Dalziel, S.R., Furyk, J., Bonisch, M. et al. A multicentre randomised controlled trial of levetiracetam versus phenytoin for convulsive status epilepticus in children (protocol): Convulsive Status Epilepticus Paediatric Trial (ConSEPT) - a PREDICT study. BMC Pediatr 17, 152 (2017).
Journal: BMC pediatrics
Abstract: Convulsive status epilepticus (CSE) is the most common life-threatening childhood neurological emergency. Despite this, there is a lack of high quality evidence supporting medication use after first line benzodiazepines, with current treatment protocols based solely on non-experimental evidence and expert opinion. The current standard of care, phenytoin, is only 60% effective, and associated with considerable adverse effects. A newer anti-convulsant, levetiracetam, can be given faster, is potentially more efficacious, with a more tolerable side effect profile. The primary aim of the study presented in this protocol is to determine whether intravenous (IV) levetiracetam or IV phenytoin is the better second line treatment for the emergency management of CSE in children. 200 children aged between 3 months and 16 years presenting to 13 emergency departments in Australia and New Zealand with CSE, that has failed to stop with first line benzodiazepines, will be enrolled into this multicentre open randomised controlled trial. Participants will be randomised to 40 mg/kg IV levetiracetam infusion over 5 min or 20 mg/kg IV phenytoin infusion over 20 min. The primary outcome for the study is clinical cessation of seizure activity five minutes following the completion of the infusion of the study medication. Blinded confirmation of the primary outcome will occur with the primary outcome assessment being video recorded and assessed by a primary outcome assessment team blinded to treatment allocation. Secondary outcomes include: Clinical cessation of seizure activity at two hours; Time to clinical seizure cessation; Need for rapid sequence induction; Intensive care unit (ICU) admission; Serious adverse events; Length of Hospital/ICU stay; Health care costs; Seizure status/death at one-month post discharge. This paper presents the background, rationale, and design for a randomised controlled trial comparing levetiracetam to phenytoin in children presenting with CSE in whom benzodiazepines have failed. This study will provide the first high quality evidence for management of paediatric CSE post first-line benzodiazepines. Prospectively registered with the Australian and New Zealand Clinical Trial Registry (ANZCTR): ACTRN12615000129583 (11/2/2015). UTN U1111-1144-5272. ConSEPT protocol version 4 (12/12/2014).
DOI: 10.1186/s12887-017-0887-8
Keywords: Convulsive status epilepticus;Paediatrics;Levetiracetam;Phenytoin;Emergency medicine;Interventional study;Randomised controlled trial
Type: Article
Appears in Sites:Gold Coast Health Publications

Page view(s)

checked on Oct 6, 2022

Google ScholarTM


Queensland Health has made reasonable efforts to label material owned by third parties, and ensure that material in this database has been reproduced with the consent of the copyright owners. Please contact us at for any queries or concerns regarding reproduction and rights.
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.